City of Philadelphia dominates state NIH funding awards, but suburbs are growing their share
Institutions within the City of Philadelphia reliably receive the majority of National Institutes of Health funding on an annual basis
June 04, 2019
- Institutions within the City of Philadelphia reliably receive the majority of National Institutes of Health (NIH) funding on an annual basis. Six years of data reveal that 55.5 percent of the $9.4 billion awarded to Pennsylvania since 2013 has come to Philly. Since 2013, the city’s funding share has barely fluctuated (from a low of 54.8 percent to a high of 57.6 percent), and its funding growth has almost tracked precisely with the state overall. 2018 NIH funding was 30.4 percent higher for PA than 2013 levels, whereas the city’s funding was 29.3 percent higher. Second place Pittsburgh has tracked similarly: its share of funding has stayed near 34 percent over the same time period.
- Philadelphia’s Pennsylvania suburbs have seen more aggressive growth in their funding: institutions in the burbs received 87.1 percent more NIH dollars in 2018 than in 2013. That said, the share of NIH money funding suburban companies and institutions remains small, representing 2.4 percent of all state funding since 2013. Nevertheless, the gains are notable and reflect the growing concentration of gene and immunotherapy companies in places like Malvern, where companies received $1.3 million in funding in 2013 and $5.8 million in 2018.
- This week’s BIO conference will bring international eyes to the region’s life sciences cluster, and specifically its strengths in genetic medicine. Iovance’s new Navy Yard building and Amicus Therapeutics’ research partnership with Penn are two recent examples of the critical mass building around gene and immunotherapy.
Source: JLL Research, NIH